The American Medical Association (AMA) has granted a CPT® Proprietary Laboratory Analyses (PLA) Code for Renayltix AI’s lead product, KidneyIntelX. The new code, 0105U, has been approved and published by the AMA CPT Editorial Panel, and is scheduled to become effective on October 1, 2019.Medicare Price for New CPT CodeA payment rate for the new code will be established for Medicare patients through the 2019 Clinical Lab Fee Schedule (CLFS) Annual Public Meeting process. Renayltix AI will shortly
Read More
Kidney Disease
Can Artifical Intelligence Solve The Chronic Kidney Disease Epidemic?
Chronic kidney disease (CKD) is a growing epidemic worldwide. Currently, there are 850 million individuals suffering from CKD globally, with 40 million in the United States alone. Of these individuals, 96 percent are not aware of having CKD, as kidney disease often exhibits no symptoms until it has progressed to a late stage. As this epidemic continues to grow, healthcare providers and organizations are working to determine how artificial intelligence (AI) can be used to analyze electronic
Read More
EarlySign Unveils Commercial Availability of AI Diabetes Risk Predictors Algorithm
Medial EarlySign – an Israeli health AI company has just announced the commercial availability of its first suite of machine learning-based predictive diabetes risk solutions. Expanding the company’s portfolio of clinical risk predictors, these new diabetes-focused AlgoMarkers are designed to help healthcare systems identify and engage patients at high risk for diabetes and downstream
Read More
FDA Grants Breakthrough Designation to RenalytixAI for AI-Enabled Diagnostic for Kidney Disease
RenalytixAI, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, today announced that it has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), for its lead diagnostic, KidneyIntelX™. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company.FDA Breakthrough Devices Program OverviewThe FDA’s Breakthrough Devices Program is a voluntary program for certain
Read More
Smartphone Detection of Chronic Kidney Disease Could Save NHS $877M Over 5 Years
Healthy.io, an Israeli-based provider of FDA-cleared smartphone-based urinalysis has announced the results from its early detection of chronic kidney disease (CKD) pilot study with 2,000 NHS patients with diabetes. The pilot found improved test compliance (raising responses to 72% among patients who had previously not responded to testing reminders) and discovered previously undiagnosed cases of CKD (10 percent of those who took the test).Financial Impact of CKD for the NHSWith a staggering
Read More
Cricket Health Raises $24M to Transform Patient-Centric Kidney Care
Cricket Health, a tech-enabled provider of integrated kidney care, today announced it has raised $24 million in Series A funding led by Oak HC/FT. Other participants in the round include additional new investors include Cigna Corporation, LifeForce Capital, iSeed Ventures, Joe Montana’s Liquid 2 Ventures, Rock Health co-founder Halle Tecco, and Virta Health co-founder Sami Inkinen. Returning investors include First Round Capital, Box Group, Nexus Ventures, Seven Peaks Ventures, Aberdare
Read More
HHS Launches KidneyX to Drive Innovation in Kidney Disease Treatment
The U.S. Department of Health and Human Services (HHS) is teaming up with American Society of Nephrology to launch the Kidney Innovation Accelerator (KidneyX), a a public-private partnership to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases. KidneyX will engage a community of researchers, innovators, and investors to enable and accelerate the commercialization of therapies to benefit people with and at risk for kidney diseases through a series of prize
Read More
